Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 16;13(5):837.
doi: 10.3390/jpm13050837.

Cortisol and the Dexamethasone Suppression Test as a Biomarker for Melancholic Depression: A Narrative Review

Affiliations
Review

Cortisol and the Dexamethasone Suppression Test as a Biomarker for Melancholic Depression: A Narrative Review

Martin M Schumacher et al. J Pers Med. .

Abstract

The dexamethasone suppression test (DST) assesses the functionality of the HPA axis and can be regarded as the first potential biomarker in psychiatry. In 1981, a group of researchers at the University of Michigan published a groundbreaking paper regarding its use for diagnosing melancholic depression, reporting a diagnostic sensitivity of 67% and a specificity of 95%. While this study generated much enthusiasm and high expectations in the field of biological psychiatry, subsequent studies produced equivocal results, leading to the test being rejected by the American Psychiatric Association. The scientific reasons leading to the rise and fall of the DST are assessed in this review, suggestions are provided as to how the original test can be improved, and its potential applications in clinical psychiatry are discussed. An improved, standardized, and validated version of the DST would be a biologically meaningful and useful biomarker in psychiatry, providing a tool for clinicians caring for depressed patients in the areas of diagnosis, treatment, and prognosis, and predicting the risk of suicide. Additionally, such a test could be a crucial part in the generation of biologically homogenous patient cohorts, necessary for the successful development of new psychotropic medications.

Keywords: Cushing’s syndrome; HPA-axis; cortisol; depression; dexamethasone suppression test; drug development; melancholia; suicide.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Shorter E., Fink M. Endocrine Psychiatry: Solving the Riddle of Melancholia. Oxford University Press; Oxford, UK: 2010.
    1. Liddle G.W. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 1960;20:1539–1560. doi: 10.1210/jcem-20-12-1539. - DOI - PubMed
    1. Carroll B.J., Martin F.I., Davies B. Resistance to suppression by dexamethasone of plasma 11-O.H.C.S. levels in severe depressive illness. Br. Med. J. 1968;3:285–287. doi: 10.1136/bmj.3.5613.285. - DOI - PMC - PubMed
    1. Carroll B.J., Feinberg M., Greden J.F., Tarika J., Albala A.A., Haskett R.F., James N.M., Kronfol Z., Lohr N., Steiner M., et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch. Gen. Psychiatry. 1981;38:15–22. doi: 10.1001/archpsyc.1981.01780260017001. - DOI - PubMed
    1. Kraemer H.C. The methodological and statistical evaluation of medical tests: The dexamethasone suppression test in psychiatry. Psychoneuroendocrinology. 1987;12:411–427. doi: 10.1016/0306-4530(87)90076-X. - DOI - PubMed

LinkOut - more resources